AGEN Stock Overview
A clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Agenus Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.65 |
52 Week High | US$23.20 |
52 Week Low | US$4.41 |
Beta | 1.36 |
11 Month Change | -9.36% |
3 Month Change | -69.79% |
1 Year Change | -78.27% |
33 Year Change | -95.69% |
5 Year Change | -91.06% |
Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Agenus: Novel Drugs That Just Are Not Novel
Jul 24There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
May 21Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
May 09Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet
Mar 29Agenus: 2024 May Finally Be The Year For A Major Turnaround
Jan 18Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Dec 22News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Nov 09A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)
Oct 04Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts
May 10VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma
Oct 12Agenus New Trials Set It Up For The Long Haul
Sep 27Agenus: It's Always Tomorrow
Sep 16Agenus GAAP EPS of -$0.17, revenue of $20.93M
Aug 09Agenus: Successfully Pulled Itself Away From Disaster
Jul 04Agenus: Not Quite Enough
Apr 19Auditors Have Doubts About Agenus (NASDAQ:AGEN)
Mar 06Agenus: Making Another Effort With The FDA
Jan 25Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains
Aug 25Agenus Multiple Value-Adding Events Ahead
Aug 18Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts
Aug 11Shareholder Returns
AGEN | US Biotechs | US Market | |
---|---|---|---|
7D | -4.1% | -1.1% | 0.6% |
1Y | -78.3% | 17.1% | 30.3% |
Return vs Industry: AGEN underperformed the US Biotechs industry which returned 17.1% over the past year.
Return vs Market: AGEN underperformed the US Market which returned 30.3% over the past year.
Price Volatility
AGEN volatility | |
---|---|
AGEN Average Weekly Movement | 20.8% |
Biotechs Industry Average Movement | 10.0% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AGEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AGEN's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 389 | Garo Armen | www.agenusbio.com |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
Agenus Inc. Fundamentals Summary
AGEN fundamental statistics | |
---|---|
Market cap | US$98.15m |
Earnings (TTM) | -US$223.67m |
Revenue (TTM) | US$159.63m |
0.6x
P/S Ratio-0.4x
P/E RatioIs AGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AGEN income statement (TTM) | |
---|---|
Revenue | US$159.63m |
Cost of Revenue | US$199.65m |
Gross Profit | -US$40.02m |
Other Expenses | US$183.65m |
Earnings | -US$223.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -10.37 |
Gross Margin | -25.07% |
Net Profit Margin | -140.12% |
Debt/Equity Ratio | -6.1% |
How did AGEN perform over the long term?
See historical performance and comparison